Triveni Bio's TRIV-509 heads to Phase 2 atopic dermatitis data in Q4 2026
The kallikrein-targeting antibody has no validated same-mechanism precedent in atopic dermatitis, making a randomized, placebo-controlled Week 16 readout the first test of the biology in humans.
Executive Summary
- A Phase 2 proof-of-concept trial testing a kallikrein-targeting antibody in atopic dermatitis is set to read out by year-end, the first human data for this specific mechanism in the indication.
- The trial filled to its enrollment target and moved to Active, not recruiting on schedule, with a stable protocol history that removes execution as a confounding factor for the upcoming result.
- No competitor shares the same target mechanism in this indication, so the readout will be judged against cytokine-blocking incumbents rather than against a direct mechanistic peer.
- The sponsor's newer, more heavily funded bispecific program builds on the same target biology, so this trial's result carries forward into how that larger program is read.
The trial
TRIV-509 is being tested in a randomized, placebo-controlled Phase 2 trial (NCT07167758) in adults with moderate-to-severe atopic dermatitis, with a primary endpoint of the percentage of participants showing improvement in AD at Week 16. The trial enrolled 95 patients across sites in the United States, Poland, Czechia, Canada, Hungary, Bulgaria, and Ukraine and is not designed as a registrational study. The company describes the trial as a proof-of-concept study, and Triveni Bio has guided to a data readout at the end of 2026, most recently narrowing that window to the fourth quarter. NCT07167758+1A Study Evaluating TRIV-509 in Atopic DermatitisNCT07167758Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthJun 17, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The mechanism
TRIV-509 is a half-life-extended monoclonal antibody that inhibits kallikreins 5 and 7, proteases the company describes as central drivers of skin barrier dysfunction in atopic dermatitis. That mechanism is distinct from the cytokine-blocking approaches behind approved atopic dermatitis therapies such as dupilumab, which targets IL-4Rα, and other agents in the broader indication that work through IL-13, IL-17A, IL-23, or JAK pathways. No competitor trial identified in the broader atopic dermatitis or kallikrein-target search shares TRIV-509's specific mechanism, leaving the kallikrein 5/7 approach without a same-target precedent to benchmark against in this indication. TriveniTriveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthJun 17, 2026
Operational read
The trial's registry history shows enrollment rising from 90 to 95 patients and status moving from Recruiting to Active, not recruiting on April 27, 2026, changes that coincide with enrollment reaching its full target. That enrollment change sits inside the routine band the operational model uses to flag concern, and the protocol-stability record shows a single enrollment-count update with no endpoint amendments and no primary-completion-date changes, a pattern consistent with a trial that filled cleanly rather than one straining to hit its target. Execution, in other words, is not the open question here; what the trial shows at Week 16 is. NCT07167758A Study Evaluating TRIV-509 in Atopic DermatitisNCT07167758
Why it matters beyond this trial
Triveni Bio raised $65 million in a Series C financing round in June 2026 to expand its atopic dermatitis pipeline, funding that the company said would support a larger Phase 2 proof-of-concept trial for TRIV-573, a bispecific antibody that also targets kallikreins 5 and 7 while additionally blocking the cytokine IL-13. Because TRIV-573 shares TRIV-509's kallikrein-targeting mechanism, the TRIV-509 readout functions as an early test of whether that shared biology produces a clinical signal at all, ahead of the larger bispecific program's own data. TriveniTriveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company GrowthJun 17, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.